TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized with SARS-CoV-2 pneumonia confirmed by RT-PCR or serology (IgA);~* PaO2/FiO2 \< 300 (not fully explained by heart failure or volume overload) or SpO2 \< 90% on room air.~Exclusion Criteria:~* Symptom onset \> 14 days;~* Neutrophil count \< 1,000/mm3;~* Platelets \< 50,000/mm3;~* ICU care at enrollment;~* On invasive mechanical ventilation at enrollment;~* Current use of experimental therapy for COVID-19 (except: azithromycin or corticosteroids)~* Uncontrolled arterial hypertension;~* Current or previous use of systemic immunosuppressive therapy in the last 30 days;~* Pregnancy or lactation;~* Estimated creatinine clearance \< 30 mL/min or receiving CRRT or intermittent hemodialysis;~* Allergy to ruxolitinib;~* Active tuberculosis;~* HIV seropositivity;~* Prior history of progressive multifocal leukoencephalopathy;~* Use of any JAK inhibitor in the last 30 days before study enrollment;~* Not qualifying according to investigators' perception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Group - ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib 5 mg PO b.i.d. for 14 days
- Placebo Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years older) with histologically proven HER2 negative adenocarcinoma or poorly differentiated carcinoma of the esophagus, GE junction tumors, and gastric cancer.~* Measurable or assessable metastatic disease.~* Performance status World Health Organization (WHO) 0-2 and life expectancy of greater than 3 months.~* No previous chemotherapy for advanced disease.~* Adequate functioning of the bone marrow, liver, and kidneys.~Exclusion Criteria:~* Breastfeeding or pregnancy.~* Active second primary cancer except in situ cancer or non-melanoma skin cancer.~* Cerebral metastases or leptomeningeal carcinomatosis.~* Severe or uncompensated concomitant medical conditions including peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm intervention study (Type: OTHER): Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Lansoprazole Preventing Gastroduodenal Stress Ulcerations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Patients with symptomatic coronary artery disease or valvular heart disease who require corrective cardiac surgery will be eligible to participate in this study.~Inclusion Criteria:~* Patients undergoing cardiovascular surgery, specifically elective coronary artery bypass graft or cardiac valve replacement surgery, at Temple University Hospital~* Able to provide informed consent~Exclusion Criteria:~* Evidence of active gastrointestinal bleeding~* Prior gastric (e.g. Billroth II) or esophageal surgery~* Pregnancy~* Pre-existing or current condition requiring acid-suppressive therapy - e.g. reflux esophagitis, gastric or duodenal ulcer~* Current use of acid-suppressive therapy, such as proton pump inhibitors or histamine type 2 receptor antagonists~* Contraindication to naso- or oro-gastric intubation (e.g. Zenker's diverticulum, esophageal stricture)~* Bleeding diathesis~* Allergy to lansoprazole~* Advanced renal disease (BUN\>40 and/or creatinine\>2.0.~* Advanced liver disease (Alkaline phosphatase, ALT, AST\>2 x normal)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age and less than 65 years of age~* BMI of at least 35 and no more than 40~* At least 2 years post-RNYGB surgery~* Initially achieved at least 60% EBL and a BMI 35 or less~* Regained at least 20% of pre-RNYGB excess weight at screening~* Stable weight or continued failure to lose weight for at least 3 months~* Enlarged gastric pouch (≥ 30 ml)~* Anatomy of upper GI judged suitable for revision using StomaphyX~* Completed successful nutritional screening~* Normal levels of vitamin D, iron/ferritin, calcium, and magnesium~* Absence of protein malnutrition confirmed by serum albumin \> 3 g/dL~* Willing to cooperate with follow-up dietary recommendations and assessment tests~* Signed Informed Consent~Exclusion Criteria:~* Previous revisional bariatric surgery after RNYGB~* Esophageal stricture or any anatomic condition that precludes passage of the StomaphyX device to the gastric pouch~* Diabetes type I~* Causal factors for weight regain other than gastric pouch enlargement~* Serious complications experienced during and/or after RNYGB such as leaks, fistula, incisional hernia, ulcers, pulmonary embolism or deep venous thrombosis~* Pregnancy or plans of pregnancy in the next 12 months~* Immunosuppression~* ASA \> 3~* Life expectancy less than one year~* An eating disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Washington DC, American Psychiatric Association, 2000~* Active substance abuse~* Plans of smoking cessation in the next 12 months~* Treatment with weight-loss prescription drug therapy within three months preceding the screening~* Intention to use prescription drug therapy or the use of over-the-counter weight-loss preparations during the current study~* Current participant in another weight-loss study or other clinical trial~* Inflammatory bowel disease~* Presence of ulceration at the gastrojejunostomy anastomosis~* Portal hypertension~* Coagulation disorders or chronic use of anticoagulants~* Any active medical condition that would preclude the patient from completing the study or would result in an unreasonable risk to the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- StomaphyX (Type: EXPERIMENTAL): Post-Roux-en-Y revisional surgery using the StomaphyX device.
- Sham Procedure (Type: SHAM_COMPARATOR): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 75 years~* Symptomatic, single-level degenerative lumbar disc disease, spondylosis or spondylolisthesis~* Failed conservative treatments~* Low risk for non-union~* Must be candidates for single-level, posteriolateral lumbar spine fusion~* Must be able and willing to give Informed Consent~* English-speaking~Exclusion Criteria:~* Smoker (any smoking ≤3 months prior to consent); (Patel et al. 2013)~* Patients with poorly controlled diabetes mellitus (HgbA1c \> 7%)~* Documented osteoporosis~* Prior lumbar spinal surgery at the same spinal level, or immediately adjacent spine level, to the level being operated on~* Back pain due to infection, tumour, or metabolic bone disease~* Terminal disease, such as HIV infection, neoplasm~* Autoimmune disease, such as rheumatoid arthritis~* Morbid obesity (body mass index (BMI) of 35 kg/m2)~* Major psychiatric illness in the last year~* History of alcohol or drug abuse in the last year~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NuCel (Type: EXPERIMENTAL): Stemcell allograft
- Demineralized Bone Matrix (DBM) (Type: ACTIVE_COMPARATOR): Demineralized Bone Matrix (DBM) bone graft substitute

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~* Age greater than or equal to 18 years.~* Histologically confirmed carcinoma of the gastrointestinal tract (esophagus, stomach, pancreas, bile duct, rectum).~* Treatment plan includes radiotherapy to the site of the gastrointestinal malignancy on an National Cancer Institute (NCI) protocol.~* Paraffin embedded tumor tissue from biopsy or surgery adequate in amount to perform polymerase chain reaction (PCR) and methylation specific PCR or willingness to undergo re-biopsy.~EXCLUSION CRITERIA:~* Inability to provide informed consent.~* Patients who have a history of prior therapeutic radiation.~* Patients with evidence of distant metastases on initial staging evaluation.~* Patients with other cancers excluding non-melanomatous skin cancers or carcinoma in situ.~* History of inflammatory bowel disease.~* History of collagen vascular disease or disease of altered collagen metabolism (end stage renal disease or hepatic fibrosis due to chronic hepatitis).~* History of hypersensitivity to radiation or a history of a disease which results in mucosal or other hypersensitivity to radiation (Ataxia-Telangiectasia, Bloom's Syndrome, Human Immunodeficiency Virus, Fanconi anemia, nevoid basal cell carcinoma syndrome, Li-Fraumeni syndrome, and Nijmegen breakage syndrome).~* Inability to return for follow-up visits.~* Patients who have previously received or are currently receiving MDX-101 (ipilimumab).~* Diagnosis of human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Markers of Tumor Burden and Radiation Toxicity (Type: None): Serum, plasma, urine, and stool samples will be collected prior to radiotherapy for participants with gastrointestinal malignancies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Cognitive Training for Postoperative Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 65 years of age or older, ASA I-III~2. Elective surgery (excluding neuro and cardiac surgery)~3. Date of surgery at least 10 days and up to one month from date of recruitment~4. Duration from induction of anaesthesia to end of anaesthesia minimum 2 hours~5. Expected post-operative hospital stay at least 48 hours~6. Able and willing to give informed consent~7. Literate~8. Willing to undergo cognitive and delirium assessments, perform daily cognitive training and able to return for follow-up assessments at 1 week, 3 months (phone call) and 1 year.~Exclusion Criteria:~1. Glasgow coma scale \< 15~2. Geriatric depression score (GDS-5) ≥ 2~3. Pre-existing psychiatric disorder or delirium~4. Severe visual, hearing or speech impairment~5. General anaesthetic within the last 6 months

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
- Cognitive Training (Type: EXPERIMENTAL): Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent atrial fibrillation~* Permanent atrial fibrillation~* Mitral valve defect~* Tricuspid valve defect~* Aortic valve defect~* Coronary artery disease~Exclusion Criteria:~* Pregnancy~* Age \< 18 or \> 75 Years~* Emergency surgery~* Left dominant coronary circulation (relative contraindication)~* Coronary arteries of the posterior wall without pathological findings: No inclusion~* Stenosis of the posterior wall vessels, supplied with a CABG (coronary artery bypass grafting): Inclusion possible~* Left ventricular ejection fraction \< 30%~* Size of the left atrium \> 7 cm~* Thrombosis of the left atrial appendage~* Leads in the coronary sinus~* Atrial flutter~* Infective endocarditis~* Reoperation~* Participation in other studies~* Life expectancy of less than 12 months~* Psychiatric disorders~* Hyperthyreosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- No Ablation (Type: NO_INTERVENTION): None
- bipolar radiofrequency ablation of persistent and permanent AF (Type: OTHER): intra operative bipolar RF ablation of persistent and permanent AF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx or unknown primary that is HPV 16 positive as determined by ISH and p16 positive as determined by IHC.~* Stage 3 or 4 disease without evidence of distant metastases~* At least one evaluable or uni- or bi-dimensionally measurable lesion by RECIST 1.1 criteria~* 18 years of age or older~* No previous surgery, radiation therapy or chemotherapy for SSCHN is allowed at time of study entry~* ECOG Performance Status of 0 or 1~* No active alcohol addiction~* Adequate bone marrow, hepatic and renal function as defined in the protocol~* Women of child-bearing potential must have a negative pregnancy test within 7 days of starting treatment~Exclusion Criteria~* Pregnant or breast feeding women or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months after~* Previous or current malignancies at other sites~* Symptomatic peripheral neuropathy of grade 2 or greater~* Symptomatic altered hearing greater than grade 2~* Other serious illnesses or medical conditions~* Patients that have experienced an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry~* Concurrent treatment with any other anticancer therapy~* Participation in an investigational trial within 30 days of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPF Induction Chemotherapy followed by Chemoradiotherapy (Type: EXPERIMENTAL): Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hurler-Scheie, Scheie form of MPS I, or Hurler 2 years after hematopoietic stem cell transplantation~  * Spinal cord compression~ * Has received intrathecal laronidase previously with good response and no significant safety concerns~ * Age greater than 8 years~ * Able to provide legal informed consent~ * Aware of clinical treatment option of observation without treatment or surgical decompression~ * Negative urine pregnancy test at screening (nonsterile females of child-bearing potential who are sexually active only)~Exclusion Criteria:~* Severe (Hurler) form of MPS I~* Desires surgical or medical treatment of spinal cord compression~* Spinal cord compression that warrants immediate surgical intervention~* Pregnancy or lactation~* Hematopoietic stem cell transplantation within 2 years of study enrollment~* Receipt of an investigational drug within 30 days of enrollment~* Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration~* Significant anti-iduronidase antibody titer~* Recent initiation of intravenous laronidase (within past 6 months)~* Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intrathecal laronidase (Type: EXPERIMENTAL): drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 years of age, AND~* Undergoing elective coronary angiography due to suspected stabile coronary artery disease~* Evidence of moderate (40%-79%) stenosis, requiring further routine assessment with FFR.~* Informed consent~Exclusion Criteria:~* Acute coronary syndrome or myocardial infarction within 7 days~* Hypoxia with oxygen saturation measured on pulse oximeter \< 90% with the patient breathing air~* Left ventricular hypertrophy on echocardiography (septum \>13mm)~* Asthma (not COPD)~* Advanced AV-block without pacemaker in situ~* Altered conscious state/inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supplemental oxygen (Type: EXPERIMENTAL): Inhalation of oxygen 6 L/min through an open face mask
- Ambient air (Type: SHAM_COMPARATOR): Breathing ambient air through an open face mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with Schizophrenia or Schizoaffective disorder, in which physicians considered the use of risperidone as treatment under clinical practice with a BMI \>25~* Patients have increased their body weight \>7% in the last year with the previous treatment even with a BMI\< 25~* Patients that have shown intolerance to a previous antipsychotic treatment~Exclusion Criteria:~* Pregnant or lactating patients~* Patients with psychiatry pathology other than Schizophrenia or schizoaffective disorder~* Patients with neurology pathology except Parkinsonism induced by neuroleptics~* Patients with other severe concomitant pathology~* Patients treated with Risperidone in the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: None): Risperidone As prescribed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility